Serum cytokines and bioumoral immunological characterization of psoriatic patients in long term etanercept treatment

P. Cordiali-Fei, M. Ardigò, A. Mastroianni, A. Giuliani, G. D'Agosto, V. Bordignon, E. Trento, A. Vento, Enzo Berardesca

Research output: Contribution to journalArticle

Abstract

The purpose of this study is to evaluate blood cytokines and immunological parameters in psoriatic patients during long-term treatment with etanercept. Forty-five subjects of both sexes affected by psoriasis with or without arthritis entered the study and were treated with etanercept according to international standard protocols. Biochemical blood analysis was carried out at baseline and during follow-up every second month. In particular, the following parameters were kept under control: antinuclear antibodies, anti-nDNA antibodies, anti-histone antibodies, blood cell count, circulating lymphocyte subtypes (CD3, CD4, CD8, CD16, CD19) and IgE. Cytokine profiles (IL-1-α, IL-1-β, IL-6, IL-8, IL-10, IL-12, INF, TNF-α) were also evaluated in blood samples during the treatment up to 1 year of follow-up. A significant decrease in PASI score (p

Original languageEnglish
Pages (from-to)643-649
Number of pages7
JournalInternational Journal of Immunopathology and Pharmacology
Volume21
Issue number3
Publication statusPublished - Jul 2008

Keywords

  • Cytokines
  • Etanercept
  • II-1
  • II-12
  • INF-gamma
  • Long-term treatment
  • Psoriasis
  • TNF-alpha

ASJC Scopus subject areas

  • Pharmacology
  • Immunology
  • Immunology and Allergy

Fingerprint Dive into the research topics of 'Serum cytokines and bioumoral immunological characterization of psoriatic patients in long term etanercept treatment'. Together they form a unique fingerprint.

  • Cite this